TrxR1 Cancer Research Results

TrxR1, thioredoxin reductase 1: Click to Expand ⟱
Source:
Type:
TrxR1 or TXNRD1 (Thioredoxin Reductase 1)
Redox Control, Stress Tolerance, and Therapy Resistance
• Many studies have found that an elevated expression of TrxR1 in breast tumors, NSCLC, HCC correlates with increased tumor aggressiveness and a poorer prognosis.
-TrxR1 expression was elevated by >50 fold in FaDu and HeLa cells, and by >20 fold in SCC-1 compared to either MSK-Leuk1 or keratinocytes.

High TXNRD1 expression often associates with:
-Advanced stage
-Therapy resistance
-Reduced survival

TrxR1 Inhibition
-Collapses redox control
-Causes rapid ROS accumulation
-Triggers apoptosis, especially in high-stress tumors


Scientific Papers found: Click to Expand⟱
5461- AF,    Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
Paraptosis↑, ER Stress↑, TrxR↓, selectivity↑, toxicity↝, ROS↑, mt-TrxR1↓, mt-TrxR2↓,
5471- AF,    Anti-Tumoral Treatment with Thioredoxin Reductase 1 Inhibitor Auranofin Fosters Regulatory T Cell and B16F10 Expansion in Mice
- vitro+vivo, Melanoma, B16-F10
TrxR1↓, AntiTum↑, ROS↑, NRF2↑, TumCD↑,
1908- AgNPs,    Exposure to Silver Nanoparticles Inhibits Selenoprotein Synthesis and the Activity of Thioredoxin Reductase
- in-vitro, Lung, A549
TrxR↓, TrxR1↓, ROS↑, ER Stress↑, TumCP↓, selenoP↓,
5862- carbop,  Cisplatin,    Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents
- Review, Var, NA
DNAdam↑, ER Stress↑, UPR↑, ATF4↑, ATF6↑, XBP-1↑, GRP78/BiP↑, NP/CIPN↝, toxicity↝, eff↑, TrxR1⇅,
7175- CHA,    Chaetocin from Chaetomium minutum
- Review, Var, NA
TrxR1↓, SUV39H↓,
7165- CHA,    The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase
- in-vitro, Cerv, HeLa
ROS↑, TumCD↑, TrxR1↓, other↝, GSR↓, Trx↓, eff↓,
7159- CHA,    ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin
- vitro+vivo, GC, HGC27 - in-vitro, GC, AGS - in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vitro, Nor, HEK293
TumCP↓, TumCCA↑, Casp↑, Apoptosis↑, TrxR1↓, ROS↑, eff↓, eff↑, PI3K↓, Akt↓, TumCG↓, cl‑PARP↑, cl‑Casp3↑, cl‑Casp9↑, cl‑Casp8↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, XIAP↓, survivin↓, TumVol↓, TumW↓, Weight∅, toxicity↓, Ki-67↓, other↝,
6225- CUR,    Natural products for enhancing the sensitivity or decreasing the adverse effects of anticancer drugs through regulating the redox balance
- Review, Var, NA
ox-Trx1↑, TrxR1↓, TrxR↓, ROS↑, GSH/GSSG↓, eff↓, Fenton↑, H2O2↑, *NRF2↑, *Keap1↓, *HO-1↑, *NQO1↑, ChemoSen↑,
1978- CUR,    Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells
- in-vitro, Cerv, HeLa
TrxR1↓, ROS↑, DNA-PK↑, eff↑, Trx↓, Trx1↓,
5152- GamB,    Gambogic Acid as a Candidate for Cancer Therapy: A Review
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumCI↓, TumMeta↓, angioG↓, eff↑, NF-kB↓, P53↑, P21↑, MDM2↓, HSP90↓, Bcl-2↓, Cyt‑c↑, Casp↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bax:Bcl2↑, ROS↑, SIRT1↓, TrxR1↓, Fas↓, FasL↑, FADD↑, APAF1↑, DNAdam↑, NF-kB↓, STAT3↓, MAPK↓, cFos↓, EGFR↓, Akt↓, mTOR↓, AMPK↑, TumCCA↑, ChemoSen↑, P-gp↓, survivin↓,
1954- GamB,    Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase
- in-vitro, HCC, SMMC-7721 cell
AntiTum↑, TrxR↓, TrxR1↓, ROS↑, Apoptosis↑, Dose∅, Dose?,
2873- HNK,    Honokiol Alleviates Oxidative Stress-Induced Neurotoxicity via Activation of Nrf2
- in-vitro, Nor, PC12
*neuroP↑, *GSH↑, *HO-1↑, *NADPH↑, *Trx1↑, *TrxR1↑, *NRF2↑, *ROS↓, *antiOx↑, *BBB↑, Dose↓,
2902- HNK,  Rad,    Honokiol Mitigates Ionizing Radiation-Induced Injury by Maintaining the Redox Balance of the TrxR/Trx System
- in-vitro, Nor, BEAS-2B
*TrxR1↑, *Trx↑, *radioP↑, *ROS↓,
2922- LT,    Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC
- in-vitro, Liver, HUH7
Half-Life↝, TumCCA↑, AKT1↓, ATF2↓, NF-kB↓, GSK‐3β↓, cMyc↓, GSTs↓, TrxR1↓, ROS↑,
5785- MET,    Metformin improves healthspan and lifespan in mice
- in-vivo, Nor, NA
*AntiDiabetic↑, *AntiAge↑, *toxicity⇅, *CRM↑, *Strength↑, *LDL↓, *AMPK↑, *TAC↑, *ROS↓, *Inflam↓, Risk↓, *cardioP↑, *ALAT↓, *NRF2↑, *SOD2↑, *TrxR1↑, *NQO1↑, *NQO2↑,
1947- PL,    Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer
- in-vitro, GC, SGC-7901 - in-vitro, GC, NA
TrxR1↓, ROS↑, ER Stress↑, mtDam↑, selectivity↑, NO↑, TumCCA↑, mt-ROS↑, Casp9↑, Bcl-2↓, Bcl-xL↓, cl‑PARP↑, eff↓, lipid-P↑,
1944- PL,    Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
- in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
ER Stress↑, TrxR1↓, ROS↑, eff↓, Bcl-2↓, proCasp3↓, BAX↓, cl‑Casp3↑, TumCCA↑, p‑PERK↑, ATF4↑, TumCG↓, lipid-P↑, selectivity↑,
2943- PL,    Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin
- in-vitro, CRC, HCT116 - in-vitro, Lung, A549 - in-vitro, BC, MCF7
TrxR1?, TumCD↑, ROS↑, GSH↓, eff↑,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
1984- PTL,    Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells
- in-vitro, Cerv, HeLa
AntiCan↑, TrxR1↓, TrxR2↓, ROS↑, Apoptosis↑, eff↓, eff↑,
4736- Se,  SFN,    Synergy between sulforaphane and selenium in protection against oxidative damage in colonic CCD841 cells
- in-vitro, Nor, CCD841
*TrxR1↑, *H2O2↓, *NRF2↑,
3183- SFN,    Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1
- in-vitro, GBM, NA
RadioS↑, TrxR1↓, ROS↑, ChemoSen↑, Prx↓,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2200- SK,    Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis
- in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, 8505C
NF-kB↓, GPx4↓, TrxR1↓, PKM2↓, GLUT1↓, Glycolysis↓, Ferroptosis↑, GlucoseCon↓, lactateProd↓, ROS↑,
2196- SK,    Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species
- Review, Var, NA
*ALAT↓, *AST↓, *Inflam?, *EMT↑, ROS?, TrxR1↓, PERK↑, eIF2α↑, ATF4↑, CHOP/DDIT3↑, IRE1↑, JNK↑, eff↝, DR5↑, Glycolysis↓, PKM2↓, ChemoSen↑, GPx4↓, HO-1↑,

Showing Research Papers: 1 to 25 of 25

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 25

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

SUV39H↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Fenton↑, 1,   Ferroptosis↑, 1,   GPx4↓, 2,   GSH↓, 2,   GSH/GSSG↓, 1,   GSR↓, 1,   GSTs↓, 1,   H2O2↑, 1,   HO-1↑, 1,   lipid-P↑, 2,   NRF2↑, 1,   Prx↓, 1,   ROS?, 1,   ROS↑, 18,   mt-ROS↑, 1,   selenoP↓, 1,   Trx↓, 3,   Trx1↓, 1,   ox-Trx1↑, 1,   TrxR↓, 4,   TrxR1?, 1,   TrxR1↓, 18,   TrxR1⇅, 1,   mt-TrxR1↓, 1,   TrxR2↓, 1,   mt-TrxR2↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AKT1↓, 1,   AMPK↑, 1,   cMyc↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 2,   lactateProd↓, 1,   PKM2↓, 3,   SIRT1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 5,   ATF2↓, 2,   BAX↓, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 5,   Bcl-xL↓, 2,   Casp↑, 2,   Casp3↑, 3,   cl‑Casp3↑, 2,   proCasp3↓, 1,   cl‑Casp8↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 1,   Cyt‑c↑, 1,   DR5↑, 1,   FADD↑, 1,   Fas↓, 1,   FasL↑, 1,   Ferroptosis↑, 1,   GRP58↓, 1,   JNK↑, 2,   p‑JNK↑, 1,   MAPK↓, 1,   Mcl-1↓, 2,   MDM2↓, 1,   Necroptosis↑, 1,   p38↑, 1,   p‑p38↑, 1,   Paraptosis↑, 1,   RIP1↓, 1,   survivin↓, 2,   TumCD↑, 3,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1,   CHOP/DDIT3↑, 1,   eIF2α↑, 1,   ER Stress↑, 5,   GRP78/BiP↑, 1,   HSP90↓, 1,   IRE1↑, 1,   PERK↑, 1,   p‑PERK↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNA-PK↑, 1,   DNAdam↑, 3,   P53↑, 1,   cl‑PARP↑, 4,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cFos↓, 1,   p‑ERK↓, 1,   FOXM1↓, 1,   GSK‐3β↓, 1,   mTOR↓, 2,   PI3K↓, 2,   Src↓, 1,   STAT3↓, 2,   TumCG↓, 2,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   FAK↓, 1,   Ki-67↓, 1,   MMP13↓, 1,   MMP3↓, 1,   MMPs↓, 1,   RIP3↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 3,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   ATF4↑, 3,   EGFR↓, 1,   NO↓, 1,   NO↑, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,   NF-kB↓, 4,   NF-kB↑, 1,   PGE2↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 4,   Dose?, 1,   Dose↓, 1,   Dose∅, 1,   eff↓, 6,   eff↑, 6,   eff↝, 1,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   EGFR↓, 1,   FOXM1↓, 1,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↑, 2,   neuroP↑, 1,   NP/CIPN↝, 1,   Risk↓, 1,   toxicity↓, 1,   toxicity↝, 2,   TumVol↓, 1,   TumW↓, 1,   Weight∅, 1,  
Total Targets: 147

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSH↑, 1,   H2O2↓, 1,   HO-1↑, 2,   Keap1↓, 1,   NQO1↑, 2,   NRF2↑, 4,   ROS↓, 3,   SOD2↑, 1,   TAC↑, 1,   Trx↑, 1,   Trx1↑, 1,   TrxR1↑, 4,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   AMPK↑, 1,   CRM↑, 1,   LDL↓, 1,   NADPH↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

NQO2↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam?, 1,   Inflam↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 1,   neuroP↑, 1,   radioP↑, 1,   Strength↑, 1,   toxicity⇅, 1,  
Total Targets: 32

Scientific Paper Hit Count for: TrxR1, thioredoxin reductase 1
4 Piperlongumine
3 chaetocin
3 Shikonin
2 Auranofin
2 Curcumin
2 Gambogic Acid
2 Honokiol
2 Sulforaphane (mainly Broccoli)
1 Silver-NanoParticles
1 carboplatin
1 Cisplatin
1 Radiotherapy/Radiation
1 Luteolin
1 Metformin
1 Parthenolide
1 Selenium
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1207  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page